Full Press Release Details
Pharmaceuticals Appoints Mr. Anthony S. Thornley to Its Board of
CA -- Nov 6, 2007 -- Transdel Pharmaceuticals, Inc. (OTC BB:TDLP.OB),
specialty pharmaceutical company focused on the development and
commercialization of non-invasive topically targeted medications, today
announced that Anthony S. Thornley has been appointed to the Company's Board
Thornley currently serves on the Board of Directors at Callaway Golf
Incorporated, Cavium Networks Inc. and Airvana Inc. From February 2002 to June
2005 he served as President and Chief Operating Officer of QUALCOMM, Inc.,
wireless communication technology and integrated circuit company. From July
to February 2002 he served as CFO and COO of QUALCOMM and from March 1994 to
February 2002 he was the CFO of QUALCOMM. Prior to joining QUALCOMM, he was
Nortel Networks, a telecommunications equipment manufacturer, for sixteen years
in various financial and information systems management positions, including
Vice President Finance and IS, Public Networks, Vice President Finance NT World
Trade and Corporate Controller Nortel Limited. He has also worked for Coopers
and Lybrand in public accounting. Mr. Thornley received his BS degree in
Chemistry from the University of Manchester, England.
delighted to have a person of Mr. Thornley's stature join our board of
directors," stated Dr. Juliet Singh, President and Chief Executive Officer
Transdel Pharmaceuticals. "His extensive knowledge and experience as a senior
executive in finance, operational and strategic roles and as a public company
director makes him a valuable addition to our board as we continue to create
value for our shareholders."
Transdel Pharmaceuticals, Inc.
Pharmaceuticals is a specialty pharmaceutical company focused on the development
and commercialization of non-invasive topically delivered medications. The
Company's lead topical drug, Ketotransdel , utilizes the Company's innovative
patented proprietary Transdel cream formulation to facilitate the passage of
ketoprofen, an NSAID, through the skin barrier to reach targeted underlying
tissue where the drug exerts its prolonged localized anti-inflammatory and
analgesic effect. The Company is also investigating other drug candidates and
treatments for transdermal delivery using the patented Transdel platform
technology for products in pain management and other therapeutic areas.
Statements which are not historical facts contained in this press release are
forward-looking statements that involve certain risks and uncertainties
including but not limited to risks associated with the uncertainty of future
financial results, additional financing requirements, development of new
products, government approval processes, the impact of competitive products
pricing, technological changes, the effect of economic conditions and other
uncertainties detailed in the Company's filings with the Securities and Exchange